CytomX Therapeutics, Inc. (CTMX) Shares Bought by Renaissance Technologies LLC
Renaissance Technologies LLC raised its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 157.5% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 234,800 shares of the biotechnology company’s stock after buying an additional 143,600 shares during the period. Renaissance Technologies LLC owned about 0.64% of CytomX Therapeutics worth $4,055,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in CTMX. Citadel Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the first quarter valued at about $313,000. Vident Investment Advisory LLC raised its stake in shares of CytomX Therapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 75,924 shares of the biotechnology company’s stock valued at $1,311,000 after buying an additional 12,652 shares in the last quarter. Hamilton Lane Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the first quarter valued at about $366,000. Russell Investments Group Ltd. purchased a new stake in shares of CytomX Therapeutics during the fourth quarter valued at about $243,000. Finally, Spark Investment Management LLC raised its stake in shares of CytomX Therapeutics by 52.5% in the first quarter. Spark Investment Management LLC now owns 101,700 shares of the biotechnology company’s stock valued at $1,756,000 after buying an additional 35,000 shares in the last quarter. 52.33% of the stock is currently owned by institutional investors.
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded up 0.989% during midday trading on Tuesday, hitting $13.785. The stock had a trading volume of 69,100 shares. The company’s market capitalization is $506.58 million. CytomX Therapeutics, Inc. has a one year low of $9.84 and a one year high of $20.02. The firm’s 50-day moving average is $14.72 and its 200 day moving average is $14.43.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.30. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. Equities analysts expect that CytomX Therapeutics, Inc. will post ($1.41) earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on CTMX shares. Cowen and Company reiterated a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a report on Wednesday, May 3rd. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. HC Wainwright reiterated a “buy” rating on shares of CytomX Therapeutics in a report on Monday, May 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $25.00 price target on shares of CytomX Therapeutics in a report on Tuesday, June 6th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $24.50.
In related news, major shareholder Robert I. Tepper sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $16.00, for a total transaction of $240,000.00. Following the completion of the transaction, the insider now directly owns 44,777 shares of the company’s stock, valued at $716,432. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean A. Mccarthy sold 4,481 shares of the stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $15.00, for a total value of $67,215.00. Following the transaction, the insider now directly owns 8,726 shares of the company’s stock, valued at $130,890. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,062 shares of company stock valued at $497,641. 8.00% of the stock is owned by corporate insiders.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.